Key facts
- Global Vascular’s last known valuation is $50.3M (Jun 2025).
- It has raised $18.8M; the latest was Early Stage VC ($6.9M) in Jun 2025.
- Notable investors include Mitsubishi UFJ Capital, J-Startup, Mitsui Sumitomo Insurance Co., Sumitomo Mitsui Trust Bank, Tokyo University of Science Investment Management — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Global Vascular
- ·The full record, as it builds
Funding rounds
No funding rounds for Global Vascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Global Vascular
Developer of a drug-eluting stent delivery system designed for the treatment of lower limb artery disease. The company's nanotechnology suppresses thrombus adhesion and allows cell integration with the stent without inhibiting it, helping medical staff to undergo stent treatment on the patients while being gentle on the body
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2022
- Website
- g-vasc.com/
- Ownership
- Privately Held (backing)
Global Vascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Global Vascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Global Vascular in its N-PORT filings yet. We sweep new filings monthly.